ERBB2 and breast cancer: Interestingly, HER2-positive CTCs did not demonstrate increased sensitivity to the HER2 inhibitor lapatinib compared to HER2-negative CTCs, suggesting a reduced dependence on HER2 signaling, unlike commercially available BC cell lines with HER2 amplification.